Health Giant CSL Wipes Out Decade of Share Price Gains on Profit Warning

CSL cuts profit outlook and flags $6.9b in new charges

CSL has cut its full-year outlook and flagged about $US5 billion ($6.9b) in additional impairments, saying a turnaround will take longer than expected after a review by its interim chief executive.

Health giant CSL wipes out decade of share price gains on profit warning

The ASX falls as CSL shares tank on a profit downgrade. More strong earnings news, demand for AI stocks and positive jobs data drove Wall Street higher. Follow the ABC News live markets blog.

ASX 200 Healthcare Giant CSL Crashes After Guidance Shock

CSL shares plunged after the healthcare giant cut earnings guidance and flagged major impairment charges tied to its kidney treatment business.

ASX Dips Heavily, CSL Shares Plummet

The Australian share market experienced significant broad losses near midday (AEST), predominantly due to a substantial plunge in global biotechnology leader CSL. Shares in the company, which develops and manufactures plasma-derived therapies, vaccines, and recombinant protein products, plummeted by nearly 20 per cent, reaching an 11-year low. This sharp decline followed CSL’s revelation of a significant $7 billion write-down and drastically rev…

CSL (ASX:CSL) Cuts FY26 Guidance and Flags US$5bn Impairment as Interim CEO Resets the Story

A 90-day review delivers the bad news in one hit, and the CSL Vifor write-down is the line investors will fixate on. CSL Limited (ASX:CSL) has done what new leadership at troubled blue chips usually does. Interim CEO Gordon Naylor used his 90-day review to clear the decks, cut FY26 guidance and flag roughly US$5 billion in additional non-cash pre-tax impairments across FY26 and FY27. Revenue for FY26 is now expected to land around US$15.2 billio…

CSL cuts FY26 guidance, flags $5bn in impairments

The CSL Ltd (ASX: CSL) share price is in focus today after the company delivered a 90-day interim CEO review and financial update, revealing revised, lower FY26 earnings guidance and plans for around $5 billion in additional asset impairments. What did CSL report? FY26 revenue expected to be around $15.2 billion (constant currency). FY26 NPATA (excluding restructuring costs and impairments) forecast at approximately $3.1 billion. Additional non…